Sun Pharmaceutical Industries Limited and Philogen S.p.A. have reported the successful conclusion of patient enrollment in the Phase III FIBROSARC trial for Soft Tissue Sarcoma (STS). All current Fibromun trials are progressing according to their...
Essential Pharma, a global specialty pharmaceutical organization dedicated to providing patients with access to low volume, clinically distinct niche pharmaceutical products in vital therapeutic fields, and Clinigen, the worldwide specialty...
Apogee Therapeutics, Inc., a biotechnology firm in the clinical stage, announced that the initial patient has received treatment in Part B of the phase 2 APEX clinical trial of APG777 for individuals with moderate-to-severe atopic dermatitis (AD)...
Ameera Shah’s Metropolis Healthcare Limited, the second-largest and most esteemed pathology laboratory chain in India, announced its partnership with Roche Diagnostics India and surrounding regions to launch the self-sampling human papillomavirus...
Tasso Inc., the premier provider of patient-focused, clinical-grade blood collection solutions, along with ARUP Laboratories, the largest nonprofit clinical and academic reference lab in the U.S., announced their partnership to create and...
Renalys Pharma, Inc., a privately owned late-stage clinical biopharmaceutical firm located in Japan, declared that it has finalized patient enrollment and achieved the target case number for its registrational phase III clinical trial of...
Neurocrine Biosciences, Inc., a prominent biopharmaceutical firm concentrating on neuroscience, revealed the commencement of a phase 3 trial to assess the efficacy, safety, and tolerability of osavampator (previously known as NBI-1065845)...
The events in Badhal demonstrate why fast and precise diagnostic methods remain vital for identifying the medical source of emergency health conditions.
Exelixis, Inc., an internationally focused oncology firm, revealed findings from a subgroup analysis of the phase 3 CABINET pivotal trial involving patients with extra-pancreatic neuroendocrine tumours (epNET) originating in the gastrointestinal...
Innate Pharma SA reported that the initial patient has been dosed in its Phase 1 trial (NCT06781983), evaluating the safety and tolerability of IPH4502, a novel Antibody-Drug Conjugate (ADC), in individuals with advanced solid tumors expressing...
, CDSCO.jpg)
